Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Exploring the protective role of Complement Receptor of the Immunoglobulin superfamily (CRIg) in models of liver ischemia reperfusion injury.
FY 2023-24
Summary
Liver ischemia-reperfusion (LIRI) is a deleterious yet inherent aspect of organ transplantation that leads to increased inflammatory damage-associated molecular patterns (DAMPs) in the transplant recipient’s circulation. Pyroptosis, a programmed lytic cell death pathway known to drive LIRI, is triggered by NLR family pyrin domain containing (NLRP3) and caspase 1 activation, culminating in plasma membrane rupture and the release of interleukin 1b (IL-1b) and DAMPs, promoting innate inflammation of resident macrophages (Kupffer cells [KCs]) and immune cell recruitment. In parallel, the complement system, another key immunity system, eliminates invading pathogens and apoptotic particles by opsonin recognition. Activation of any of the three complement pathways concludes in the generation of C3a and C3b fragments from the C3 protein. C3b fragments deposit on the surfaces of microbial or apoptotic surfaces, which are then recognised and phagocytosed by Complement Receptor of the Immunoglobulin superfamily (CRIg; aka VSIG4) in a non-inflammatory manner through an unknown endocytic pathway. More importantly, CRIg has been shown to be highly expressed in KCs, with the ability to supress transcription of NLRP3 and IL1b when bound to ligands. Therefore, we hypothesized that CRIg activation confers hepatoprotective effects by preventing pyroptosis in KCs amidst LIRI, reducing tissue inflammation. To uncover this, we will determine the cascade required to phagocytose ligands of CRIg, and the effects this process may have on the immunophenotype of macrophages, as well as their response to hypoxic, LIRI-mimicking conditions. Lasty, in vivo, we will establish a role of CRIg in LIRI by administering activating-CRIg antibodies in wild-type mice undergoing LIRI or sham surgeries.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
505813
Name
Aguilar Fiorelle C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the protective role of Complement Receptor of the Immunoglobulin superfamily (CRIg) in models of liver ischemia reperfusion injury.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Complement System; Crig; Immunology; Inflammation; Ischemia Reperfusion Injury; Kupffer Cells; Liver; Phagocytosis; Pyroptosis; Signalling
Abstract
Liver ischemia-reperfusion (LIRI) is a deleterious yet inherent aspect of organ transplantation that leads to increased inflammatory damage-associated molecular patterns (DAMPs) in the transplant recipient’s circulation. Pyroptosis, a programmed lytic cell death pathway known to drive LIRI, is triggered by NLR family pyrin domain containing (NLRP3) and caspase 1 activation, culminating in plasma membrane rupture and the release of interleukin 1b (IL-1b) and DAMPs, promoting innate inflammation of resident macrophages (Kupffer cells [KCs]) and immune cell recruitment. In parallel, the complement system, another key immunity system, eliminates invading pathogens and apoptotic particles by opsonin recognition. Activation of any of the three complement pathways concludes in the generation of C3a and C3b fragments from the C3 protein. C3b fragments deposit on the surfaces of microbial or apoptotic surfaces, which are then recognised and phagocytosed by Complement Receptor of the Immunoglobulin superfamily (CRIg; aka VSIG4) in a non-inflammatory manner through an unknown endocytic pathway. More importantly, CRIg has been shown to be highly expressed in KCs, with the ability to supress transcription of NLRP3 and IL1b when bound to ligands. Therefore, we hypothesized that CRIg activation confers hepatoprotective effects by preventing pyroptosis in KCs amidst LIRI, reducing tissue inflammation. To uncover this, we will determine the cascade required to phagocytose ligands of CRIg, and the effects this process may have on the immunophenotype of macrophages, as well as their response to hypoxic, LIRI-mimicking conditions. Lasty, in vivo, we will establish a role of CRIg in LIRI by administering activating-CRIg antibodies in wild-type mice undergoing LIRI or sham surgeries.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Aguilar, Fiorelle C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~